Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C

Digestive Diseases and Sciences

Volumn 56, Issue 4, 2011, Pages 1222-1228

  AlQaraawi, Abdallah M ^a   Sanai, Faisal M ^b   Al Husseini, Hussa ^c   Albenmousa, Ali ^c   AlSheikh, Abdulmalik ^a   Ahmed, Lubna Rizwan ^a   Hersi, Ahmad ^a   Al Otaibi, Molfi M ^c   Syed, Mohammed ^c   Ali, Safiyya M ^d   Al Hamoudi, Waleed ^a,d   Alswat, Khalid A ^a,d   Abdo, Ayman A ^a,d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Fibrosis; Genotype 4; Hepatitis C; Histology; Inflammation; Interferon; NAS score; Steatosis

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; SAUDI ARABIA; SUSTAINED VIROLOGICAL RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIVIRAL AGENTS; BIOPSY; BODY MASS INDEX; DIABETES MELLITUS; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPERLIPIDEMIAS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREVALENCE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX;

EID: 79955610425     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1417-9     Document Type: Article

References (17)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;7:2436-2441. (Pubitemid 46929498)
2. Soresi M, Tripi S, Franco V, et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int. 2006;26:1119-1125. (Pubitemid 44541753)
3. Osoba AO. Hepatitis C virus genotypes in Saudi Arabia. Saudi Med J. 2002;23:7-12. (Pubitemid 34187712)
4. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol. 2006;14:6756-6765. (Pubitemid 44811395)
5. Alaei M, Negro F. Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab. 2008;34:692-700.
6. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.
7. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321. (Pubitemid 40770284)
8. Khattab MA, Abdel-Fattah ME, Eslam M, et al. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. J Clin Gastroenterol. 2010; (Epub ahead of print).
9. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a metaanalysis of individual patient data. Gastroenterology. 2006;130:1636-1642.
10. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol. 2007;102:634-641. (Pubitemid 46328141)
11. Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008;15(2):129-136.
12. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010; (Epub ahead of print).
13. Esmat G, El Akel W, Metwally M, et al. Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian J Gastroenterol. 2009;28:45-48.
14. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40:484-490. (Pubitemid 38230851)
15. Akuta N, Suzuki F, Tsubota A, et al. Efficacy of interferon monotherapy to 394 consecutive naïve cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol. 2002;37:831-836. (Pubitemid 35404223)
16. Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1181-1191. (Pubitemid 46650297)
17. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38:639-644. (Pubitemid 37052150)